12 July 2024 | Friday | News
Image Source : Public Domain
Both parties will leverage their respective expertise in generative AI technology and practical experience of drug development from target discovery to Investigational New Drug (IND) application, to create a next-generation antibody drug discovery platform driven by AIGC and jointly promote trilateral cooperation with leading innovative pharmaceutical companies or biotechs to enhance the efficiency of new drug R&D and help pharmaceutical R&D enterprises improve global competitiveness.
In this strategic cooperation, Sanyou Bio will integrate BioGeometry's proprietary generative AI antibody design platform (GeoBiologics). Both parties will invest their respective advantageous resources, professional technologies and experiences to create an outstanding Dry-Wet antibody R&D platform by integrating BioGeometry's leading AI algorithm dry lab platform with Sanyou Bio's wet lab capabilities. This platform will be utilized for the development of more large molecule drug pipelines and the incubation of innovative projects, paving the way for further market expansion.
Sanyou has built a world-leading high-throughput, and integrated R&D platform for innovative antibody drugs, accumulating and forming the world's largest antibody library and other technical resources. The antibody library construction platform, based on nine super-trillion antibody libraries as its core, has a capacity of up to 10 trillion. It seamlessly integrates phage display and mammalian cell protein expression of molecule generation technologies. Equipped with fully automated screening and integrated antibody drug R&D capabilities, it is suitable for challenging innovative targets and the development of high-difficulty new molecules, with a focus on generating molecules with characteristics such as "close to natural, high affinity, and excellent developability". The platform has strong wet experimental capabilities and data advantages.
As a leading AI-driven protein design enterprise, BioGeometry has developed atomic-level geometric deep learning models which learn from massive data to effectively save the time and costs in antibody design, improve economic efficiency and success rates. Moreover, BioGeometry has achieved a closed-loop between dry and wet lab on its generative AI antibody discovery SaaS platform, GeoBiologics. Molecules generated or optimized by AI models are further validated and screened through high-throughput wet-lab experiments. At the same time, the experimental data is fed back to the AI models to enhance prediction accuracy and confidence. Through multiple rounds of AI design and wet-lab validation, functional molecules can be discovered more efficiently.
Dr. Guojun Lang, founder and CEO of Sanyou Bio, remarked: "BioGeometry's generative AI technology has enabled Sanyou to achieve intelligent and digital transformation of our antibody drug R&D platform, further strengthening our advantages in new drug discovery and preclinical integration. We believe that the AIGC antibody drug discovery platform created through our collaboration with BioGeometry will provide more innovative solutions for new drug R&D enterprises, accelerate the preclinical research of more new drugs, and even facilitate their entry into clinical trials, thereby enhancing global competitiveness of pharmaceutical R&D enterprises."
Dr. Jian Tang, founder and CEO of BioGeometry, stated: "We look forward to jointly creating with Sanyou Bio a cutting-edge AI-enabled antibody discovery platform combining dry and wet labs. This platform aims to become an innovative model for AI-empowered new drug R&D leading the industry, and accelerate the development of antibody drug R&D and fully enter the era of artificial intelligence. We hope to incubate and advancing more large-molecule drug pipelines through our platform, jointly overcoming more challenges in antibody drug R&D, and making substantive contributions to the progress of global disease treatment."
Most Read
Bio Jobs
News
Editor Picks